Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Expo on Google News
SYS-CON.TV
Cloud Expo & Virtualization 2009 East
PLATINUM SPONSORS:
IBM
Smarter Business Solutions Through Dynamic Infrastructure
IBM
Smarter Insights: How the CIO Becomes a Hero Again
Microsoft
Windows Azure
GOLD SPONSORS:
Appsense
Why VDI?
CA
Maximizing the Business Value of Virtualization in Enterprise and Cloud Computing Environments
ExactTarget
Messaging in the Cloud - Email, SMS and Voice
Freedom OSS
Stairway to the Cloud
Sun
Sun's Incubation Platform: Helping Startups Serve the Enterprise
POWER PANELS:
Cloud Computing & Enterprise IT: Cost & Operational Benefits
How and Why is a Flexible IT Infrastructure the Key To the Future?
Click For 2008 West
Event Webcasts
Ablynx to Present Rheumatoid Arthritis Data at 2012 American College of Rheumatology Annual Meeting

GHENT, BELGIUM -- (Marketwire) -- 11/09/12 -- Ablynx (EURONEXT BRUSSELS: ABLX) today announced that it will present data from two Nanobody®-based products in rheumatoid arthritis (RA) at the annual meeting of the American College of Rheumatology (ACR) from 10-14 November in Washington D.C., USA. The poster presentations will be based on the outcome of pre-clinical and clinical studies that have previously been disclosed.

Ablynx will have three poster sessions including two posters on its novel IL-6R Nanobody, ALX-0061, and one poster on its novel anti-TNFa Nanobody, ozoralizumab (ATN-103).

ALX-0061 is a bi-specific IL-6R targeting Nanobody with monovalent binding to IL-6R and human serum albumin. Translational modelling studies resulted in a novel first-in-human design that combined a single-ascending dose, a multiple ascending dose and clinical POC using pharmacokinetics, biomarker and early clinical read outs as decision tools. Earlier reported results from the 12 week interim analysis of the Phase I/II study demonstrate that ALX-0061 has the potential to become a best-in-class IL-6R inhibitor in RA with a strong efficacy profile based on a 80% ACR20 response, a 60% DAS28-CRP remission rate, and a fast onset of DAS28-CRP remission; and an excellent safety profile with no serious infections, no decrease in neutrophils, no clinically significant increases in liver enzymes and no increases in lipid levels (cholesterol and LDL) being observed.

Ozoralizumab, ATN-103, a novel TNFa inhibitor, is a trivalent, bi-specific Nanobody that potently neutralises TNF and binds to human serum albumin to increase its in vivo half-life. The results from the Phase II open-label extension study demonstrated that ozoralizumab enables highly effective and well-tolerated individualised treatment. The specific molecular features of Nanobodies, including their small size, low immunogenic potential and manufacturability, contributed to the desired outcome, with the majority of patients showing marked improvement in their disease activity. Moreover, the once-induced remission could be maintained at doses less than 80mg monthly. This treatment approach could be beneficial to patients and minimise treatment costs.

Details on the poster sessions
Abstract/poster #336:
Pre-clinical development of ALX-0061, an anti-IL-6R Nanobody for therapeutic use in rheumatoid arthritis with a high in vitro affinity and potency and a competitive in vivo pharmacological profile - 11 November
Abstract/poster #1307: Anti-IL-6 receptor Nanobody (ALX-0061) seamless "first-in-human" Phase I/II POC study in patients with active RA on stable MTX treatment- 12 November
Abstract/poster #1311: A novel individualised treatment approach in open-label extension study of ozoralizumab (ATN-103) in subjects with rheumatoid arthritis on a background of methotrexate - 12 November

About Ablynx
Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 25 programmes in the pipeline and seven Nanobodies at clinical development stage. Ablynx has ongoing research collaborations and significant partnerships with major pharmaceutical companies including Boehringer Ingelheim, Merck KGaA, Novartis and Merck & Co. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.

press release in pdf: http://hugin.info/137912/R/1656461/535559.pdf

For more information, please contact
Ablynx:
Dr. Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193
+32 (0)473 39 50 68
e: edwin.moses@ablynx.com

Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch@ablynx.com
Follow us on Twitter @AblynxABLX

M:Communications:
Mary-Jane Elliott, Amber Bielecka, Claire Dickinson
t: +44 207 920 2330
e: ablynx@mcomgroup.com

About Marketwired .
Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Cloud Developer Stories
Due of the rise of Hadoop, many enterprises are now deploying their first small clusters of 10 to 20 servers. At this small scale, the complexity of operating the cluster looks and feels like general data center servers. It is not until the clusters scale, as they inevitably do, ...
Security is critical to Internet of Things (IoT) adoption because we want to make sure we can trust the sensors, actuators, rules engines and other connected componentry we embed in every element of our existence. Bringing this down to earth is as easy as pointing out that people...
Almost everyone sees the potential of Internet of Things but how can businesses truly unlock that potential. The key will be in the ability to discover business insight in the midst of an ocean of Big Data generated from billions of embedded devices via Systems of Discover. Busin...
The old monolithic style of building enterprise applications just isn't cutting it any more. It results in applications and teams both that are complex, inefficient, and inflexible, with considerable communication overhead and long change cycles. Microservices architectures, whi...
Software development, like engineering, is a craft that requires the application of creative approaches to solve problems given a wide range of constraints. However, while engineering design may be craftwork, the production of most designed objects relies on a standardized and au...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021



SYS-CON Featured Whitepapers
ADS BY GOOGLE

Breaking Cloud Computing News

The U.S. business group of Sun Life Financial Inc. (NYSE: SLF, TSX: SLF) announced ...